Celldex Therapeutics, Inc.

NASDAQ:CLDX

Biotechnology

Healthcare
$27.55 +0.47%

+$0.16 today

Market cap
$2.16B
Beta
0.93
P/E (TTM)
-7.8
EPS (TTM)
-$4.26
52W Low $19.52High $35.79

Volume 0.68M

Average 0.94M

CLDX Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Celldex Therapeutics, Inc.NASDAQ: CLDX

Stock-Based Compensation · Q3 FY2026 · quarter ended Sep 2026

Stock-based compensation growth accelerates

Q3 FY2026 stock-based compensation of $10.97M rose 24.7% year over year, ahead of the -0.7% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 30.5% from the prior quarter.

Context

  • Stock-based compensation amounted to 2414.5% of revenue in FY2025, up 1926.7 pp from a year earlier.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +24.7% holds above the trailing-twelve-month pace of -0.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$10.97M+30.5% QoQ
Last fiscal yearDec 2025
$36.22M+5.8% YoY
LTMSep 2026
$36.81M-0.7% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+24.7%——
1 year+5.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
36.22M USD
Year-over-year change
+5.8%
4-year CAGR
+41.8%

Stock-Based Compensation vs competitors

How CLDX compares with its peers on the latest reported figures

  • CLDX's LTM Sep 2026 stock-based compensation of $36.81M is the 5th largest of the 10 companies compared; the peer median is $12.55M.
  • Its year-over-year change of -0.7% is the 5th highest of 8, against a peer median of +8.7%.
  • Stock-based compensation amounts to 32869.6% of revenue for CLDX, versus a peer median of 8.3%.
CLDX Competitors Peer median
Stock-Based Compensation for CLDX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RCUSArcus Biosciences, Inc.LTM Jun 2026$63M -6.0%-2.6%53.8%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$40.66M +8.7%+10.5%5.8%
XNCRXencor, Inc.LTM Jun 2026$39.03M +10.2%-4.0%37.2%
IMNMImmunome, Inc.LTM Sep 2026$37.41M +60.8%+68.9%—
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$36.81M -0.7%—32869.6%
MGNXMacroGenics, Inc.LTM Mar 2026$12.55M -55.6%-11.3%8.0%
CMPXCompass Therapeutics, Inc.LTM Mar 2026$10.93M +20.5%+16.2%—
AGENAgenus Inc.LTM Mar 2026$10.29M -14.6%-1.8%8.3%
ADAGAdagene Inc.LTM Jun 2024$7.27M —-29.1%891.4%
CGENCompugen Ltd.LTM Dec 2025$0 ——0.0%
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding CLDX) $12.55M+8.7%-2.2%8.3%

Competitors are the stored peer set for CLDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(70.51M)(112.33M)(141.43M)(157.86M)(258.76M)
Depreciation & Amortization3.07M2.9M3.01M3.18M3.38M
Deferred Income Tax(227K)0000
Stock-Based Compensation8.95M023.89M34.24M36.22M
Change in Working Capital(1.05M)(3.9M)13.46M(21.6M)14.06M
Accounts Receivables1.57M(175K)(2.28M)1.93M(1.32M)
Inventory00000
Accounts Payables3.65M3.12M9.38M11.63M11.03M
Other Working Capital(6.28M)(6.85M)6.36M(35.16M)4.34M
Other Non-Cash Items(1.14M)9.6M(6.22M)(15.73M)(5.84M)
Operating Cash Flow(60.91M)(103.73M)(107.29M)(157.78M)(210.95M)
Capital Expenditures(1.25M)(1.83M)(1.82M)(1.92M)(2.71M)
Acquisitions (Net)27K69K000
Purchases of Investments(389.88M)(188.97M)(424.56M)(789.92M)(384.5M)
Sales of Investments174.95M280.67M320.6M501.71M596.29M
Other Investing Activities00000
Investing Cash Flow(216.16M)89.94M(105.78M)(290.13M)209.07M
Debt Repayment00000
Common Stock Issued269.89M4.08M216.22M432.3M2.39M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.48M02.24M9.15M0
Financing Cash Flow272.37M4.08M218.46M441.45M2.39M
Effect of Forex Changes00000
Net Change in Cash(4.69M)(9.71M)5.39M(6.46M)515K
Free Cash Flow(62.16M)(105.56M)(109.11M)(159.7M)(213.66M)

Celldex Therapeutics, Inc.

NASDAQ:CLDX

Intrinsic Alpha fair value

Locked

Current Price

$27.55

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.